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Outcomes of pancreas transplantation from donors with high alcohol 
consumption are poorly described.  
The UK Transplant Registry was used to determine if donor alcohol intake 
influenced pancreas survival in simultaneous pancreas-kidney (SPK) 
transplants performed between 2006-2012 (n=770). Recipients were stratified 
by donor alcohol intake: group I (n=122) – high recent alcohol intake (>21 or 
>14 units of alcohol/week in males or females, respectively) or previous 
alcohol abuse; group II (n=648) – low/unknown current intake and no previous 
alcohol abuse.  
Median current alcohol intake was higher in group I than group II: 36.3 vs 10 
units/week; p<0.001. One- and five-year pancreas graft survivals were 88.5% 
and 73.6% in group I; 87% and 74.9% in group II. There was no difference in 
unadjusted graft survival between groups I and II (p=0.76), and no difference 
between group II and a sub-group of group I with a donor history of alcohol 
abuse and high current intake (p=0.26), or from donors with current alcohol 
consumption of >50 units/week (p=0.41).  
Pancreas donors with past alcohol abuse or current high intake are common, 
and graft outcomes appear to be acceptable. This analysis suggests that high 





It is well recognised that excessive alcohol consumption can injure the 
pancreas (1). Alcohol can exert its deleterious effects on the pancreas by 
activating both acinar and stellate cells, resulting in autodigestive injury, 
progressive necro-inflammation and increased synthesis of extracellular 
matrix proteins leading to pancreatic fibrosis (2-4). In addition, chronic excess 
alcohol intake has harmful effects on the endocrine function of the pancreas 
with reduction in -cell mass and insulin resistance (5, 6). There is also some 
evidence which suggests that high alcohol intake is associated with an 
increased risk of pancreatic adenocarcinoma (7-9). Therefore it is 
understandable that transplant surgeons are reluctant to implant pancreases 
from donors with a history of high alcohol consumption (10, 11). However, 
outcomes of pancreases transplanted from donors with high alcohol intake 
have been poorly described.  
 
A large retrospective analysis of US donors found no statistically significant 
association between donor alcohol use and diminished pancreas graft 
survival, though no details were given on how alcohol consumption was 
quantified, or how many pancreases from donors with high alcohol use were 
transplanted (12). It is particularly important to examine this issue in detail as 
alcohol consumption appears to be rising, both in the UK, and worldwide (13, 
14).  
 
Simultaneous pancreas-kidney (SPK) transplantation has been shown to 
provide a strong survival benefit for selected patients with insulin-dependent 
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diabetes mellitus and end-stage renal failure (15). Therefore, the impact of 
donor alcohol intake on pancreas graft survival requires further investigation 
in order to prevent inappropriate decline of pancreases that may confer a 
survival benefit to those on the waiting list.  
 
In this study, the UK Transplant Registry was analyzed to determine the 
frequency of high donor alcohol intake in SPK transplantation, and to examine 
whether donor alcohol intake had an impact on subsequent pancreas allograft 
survival. We also performed subgroup analyses to determine whether past 




Materials & Methods 
Data on SPK transplants performed between 1 January 2006 and 31 
December 2012 were identified from the National Health Service Blood and 
Transplant (NHSBT) UK Transplant Registry. During this time period there 
were 9 pancreas transplant units in the UK, but one unit performed only three 
SPK transplants and closed in 2006. The UK pancreas allocation schemes 
between 2006 and 2012 are described elsewhere (16).  
 
Organs were procured from donation after brain death (DBD) or Maastricht 
category III and IV donation after circulatory death (DCD) donors. Study 
exclusion criteria were chosen to minimize possible differences in baseline 
donor, recipient, and operative characteristics between donors with or without 
a history of high alcohol intake. Exclusion criteria were: Maastricht category I 
or II DCD donors, pediatric donors (aged less than 18 years), donor age >55 
years, donor body mass index (BMI) <20 or >30 kg/m2, and recipients of 
previous solid organ transplants.  
 
Donor alcohol intake was recorded electronically by donor co-ordinators after 
interviews with donor families where questions were specifically asked on 
donor alcohol intake, including current alcohol intake and past history of 
alcohol abuse. Alcohol abuse was not specifically defined; duration of alcohol 
abuse was not generally recorded. Donor co-ordinators also examined the 
donor’s medical records, and, where possible, contacted the donor’s family 
physician prior to donation.  
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Where the current volume and type of alcohol ingested by the donor was 
documented by the donor co-ordinator, the units of alcohol consumed per 
week in the period prior to donation were calculated (17). In the UK, one unit 
of alcohol is defined as 10 ml of pure alcohol (18); for example, two standard 
(175 ml) glasses of white wine (13% alcohol by volume) per day is equivalent 
to 32.2 units/week. The UK government recommended maximum alcohol 
intake of 21 units/week for men and 14 units/week for women was used to 
define high / low current alcohol intake (19, 20). 
 
Recipients were initially stratified into two groups based on the recorded 
donor alcohol history: group I – high current intake or past history of alcohol 
abuse; group II – low (or unknown) current alcohol intake and no known 
history of alcohol abuse. For some analyses, group I was further subdivided: 
Ia – high current intake and no (or unknown) past history of alcohol abuse; Ib 
– past history of alcohol abuse but current alcohol intake unknown; Ic – past 
history of alcohol abuse and high current alcohol intake; Id -  past history of 
alcohol abuse and low current intake. In addition, within group I, donors with 
current alcohol intake >50 units per week were also identified. 
 
Pancreas graft failure was defined as return to insulin dependence, with 
censoring for death with a functioning graft and grafts still functioning at the 






Differences in donor and recipient characteristics between the two groups 
were determined using Fisher’s exact test for categorical variables and the 
Wilcoxon rank sum test for continuous variables. Survival functions were 
estimated according to the Kaplan–Meier method, with groups compared 
using the log-rank test. P < 0.05 was considered significant.  
 
Univariate Cox proportional hazards models were used to identify variables 
associated with pancreas graft survival. Hazard ratios (HRs) and 95% 
confidence intervals were calculated for each variable. A multivariate Cox 
proportional hazards model was used to determine if donor alcohol 
consumption was associated with pancreas graft survival after adjusting for 
other variables known to affect pancreas graft survival (donor gender, age, 
BMI, cause of death, graft cold ischemic time [CIT] and recipient age). 
Statistical analyses were performed using PRISM version 6 (GraphPad 
Software, La Jolla, CA, USA) and R: A Language and Environment for 







During the study period, 770 SPK transplants met our inclusion criteria. Based 
on the history of donor alcohol consumption, there were 122 (15.8%) 
recipients in group I and 648 (84.2%) in group II.  
 
Donor, recipient and operative characteristics 
Donor, recipient, and operative characteristics are shown in Table 1. Donors 
in group I were older, more likely to be male, and were less likely to have had 
an atraumatic cause of death when compared to donors in group II. As 
expected, donors in group I had a current weekly alcohol intake that was 
much higher than those in group II. There were no statistically significant 
differences in recipient variables between the two groups. Pancreas cold 
ischemic time (CIT) was significantly longer in group II than group I, although 
CITs were generally short in both groups. 
 
Detailed analysis of donor alcohol intake was undertaken. Data on current 
alcohol intake were available for 130 donors (16.9%); 88 in group I (72.1%) 
and 42 in group II (6.5%). These data are shown in Figure 1 and stratified 
according to donor gender. Twenty-six donors had current alcohol intake >50 
units per week; this equates to more than 7 single shots of spirits (25 mL of 
40% alcohol by volume) per day. For group I donors, the median (IQR) 
alcohol intake was higher in males than females (26 (13.3-49.7) versus 21 
(8.6-41.5) units per week), but this did not reach statistical significance 
(p=0.11). Unsurprisingly, the majority of donors within group I had a past 
history of alcohol abuse (69/122 – 57%). Overall, history of alcohol abuse was 
 10 
documented as “unknown” for 20 donors (2.6%); three in group I (2.5%) and 
17 in group II (2.6%). 
 
In order to determine if a past history of alcohol abuse, or high current intake 
(or both), were associated with pancreas graft survival, further stratification of 
group I was undertaken (Table 2).  The majority of donors in group I had high 
current intake and no (or unknown) past history of alcohol abuse (group Ia). 
Of note, group Ic (n=37) contained donors with a past history of alcohol abuse 
and high current intake, with a median (IQR) alcohol consumption of 50 (31.5-
70.7) units per week.  
 
Over the study period the usage of pancreases from donors with a high 
current alcohol intake or past history of alcohol abuse did not change 
(Supplementary Figure 1). There were variations between centers in the use 
of donors with high alcohol intake (Supplementary Figure 2).  
 
Graft and patient survival 
There were 8 deaths (6.6%) in group I and 60 (9.3%) in group II recipients 
within the study period (Figure 2a); there was no statistically significant 
difference in overall patient survival between the two groups (p=0.39). 
 
Unadjusted death-censored pancreas graft survival was similar for both 
groups (Figure 2b). One- and five-year pancreatic graft survivals were 88.5% 
and 73.6% in group I and 87% and 74.9% in group II, respectively. Overall, 
there was no evidence of a difference in unadjusted graft survival between the 
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two groups (p=0.76).  Graft survival did not significantly differ between the 
sub-groups of group I, and group II (p=0.11; Figure 2c), nor between groups 
Ic and II when these were compared directly (p=0.26). There was no 
difference in death-censored pancreas graft survival in SPK transplants from 
donors with current alcohol consumption of >50 units per week (n=26), versus 
donors in group II (p=0.41; graph not shown). 
 
In a univariate Cox proportional hazards regression analysis (Table 3), 
significant factors associated with pancreas graft survival were donor age 
(p=0.02) and pancreas CIT (p=0.02). In a multivariate Cox regression analysis 
(Table 3), only pancreas CIT was associated with graft survival (HR=1.05 per 
hour, p=0.02). Donor alcohol intake (current, or past history of abuse) was not 






This study investigated the effect of donor alcohol consumption on pancreas 
graft survival. Donor alcohol consumption above recommended UK thresholds 
is not uncommon in SPK transplants, and a small proportion of donors (4.8%) 
have a history of both alcohol abuse and high current intake. In both 
univariate and multivariate analyses, donor alcohol intake appeared to have 
no deleterious impact on medium-term pancreas graft survival. Furthermore, 
analyses of subgroups of donors that had the strongest pre-morbid alcohol 
history did not reveal significantly worse pancreas graft survival.  
 
The findings of this study are highly relevant to the utilisation of donor 
pancreases. Previous work has shown that a high proportion of pancreases 
that are offered for allocation are not transplanted, often due to perceived 
unfavorable donor characteristics (e.g. age, BMI, elevated serum amylase) or 
the appearance or consistency of the pancreas at the time of recovery of 
organs or bench-work (21-25). Furthermore, the pancreas is more vulnerable 
to intra-operative injury than other abdominal organs during recovery of 
organs (26). As a result, the conversion rate from potential pancreas donor to 
implantation in a recipient is low; registry data show that only 70% of potential 
donor pancreases offered for donation are recovered, and of these, a further 
30-50% are discarded after recovery of organs has been completed (26, 27). 
If pancreases are not utilized due to a perceived risk of high donor alcohol 
intake this will prolong waiting times for patients listed for a SPK transplant. 
The results of this study suggest that high donor alcohol intake is not a 
reason, in itself, to decline a pancreas offer or a procured pancreas.  
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This is perhaps surprising, as excess alcohol consumption has been shown to 
be consistently associated with development of pancreatitis, with the risk 
rising in a dose-dependent manner (28). A minimum of 6–12 years of 
approximately 80 mL or more of alcohol per day is considered necessary for 
the development of clinically evident pancreatitis. The pathophysiologic 
pathways underlying alcohol-induced pancreatitis have not yet been fully 
elucidated, though it is known that direct acinar cell damage is mediated by 
alcohol and its metabolites (e.g. acetaldehyde and fatty acid ethyl esters), and 
that inflammatory cell recruitment and activation are critical components of 
alcoholic pancreatitis (2, 29, 30). The production of pro-inflammatory 
cytokines, e.g. TNFα, can in turn activate pancreatic stellate cells to develop a 
myofibroblastic phenotype, leading to fibrin deposition and scarring (31, 32). 
Chronic alcohol consumption is therefore the major risk factor for chronic 
pancreatitis, with development of pancreatic fibrosis and progressive loss of 
normal parenchymal architecture, potentially leading to exocrine and 
endocrine pancreatic insufficiency, and increasing the risk of pancreatic 
cancer (33, 34).  
 
A possible explanation for the apparent lack of association between donor 
alcohol consumption and pancreas graft survival is that only donor 
pancreases with minimal or absent macroscopic features of pancreatic 
pathology are likely to be transplanted. Macroscopic findings consistent with 
chronic pancreatitis have been reported in only 18% of autopsies performed 
on patients with a history of alcohol abuse and liver disease, implying that 
many could have had normal functioning pancreases (35). As the effect of 
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alcohol on pancreatic inflammation is influenced by other environmental or 
genetic factors (e.g. ethnicity and polymorphisms in ethanol-metabolizing 
enzymes), less than 10% of heavy drinkers develop clinically significant 
pancreatitis (28, 36-39). All pancreases should be assessed carefully at 
bench-work; those from donors with high alcohol intake should be inspected 
especially carefully for the presence of fibrosis, fatty infiltration, pancreatitis, 
and parenchymal masses. 
 
Although our study is the first large investigation that specifically addresses 
the impact of donor alcohol intake on pancreas graft survival, the authors 
acknowledge its limitations. Firstly, quantifying donor alcohol intake through 
questioning of the donor family at a highly stressful time is likely to be 
somewhat imprecise. It is difficult to estimate the magnitude of any potential 
bias, as validation of donor alcohol intake is not feasible. In many cases, the 
donor alcohol history was unknown, and it is possible that a significant 
number of donors in group II had a heavy alcohol intake, reducing the 
likelihood of finding an association between alcohol consumption and poor 
graft outcome. Duration of donor alcohol abuse was not generally recorded 
and the term ‘alcohol abuse’ was not defined. Secondly, we chose a threshold 
for excess alcohol intake in donors as that set by UK government guidelines 
on ‘safe’ drinking (20, 40). Regular alcohol consumption above this level 
represents an increase in the lifetime risk of death by 1%, but this long-term 
risk may not be relevant in the context of SPK transplantation. However, sub-
group analysis of those donors known to have very high alcohol intake did not 
identify this as a poor prognostic factor. It is possible that this group was 
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under-powered to detect an association. Thirdly, it is possible that high donor 
alcohol intake may be relevant in more ‘marginal’ donors (e.g. aged >55 
years, BMI >30 kg/m2); however, the number of pancreases implanted from 
such donors during the study period was small, and as surgeons would be 
expected to be less likely to implant pancreases from older, heavier donors 
with high alcohol intake, this would make outcome analyses more unreliable. 
Fourthly, due to lack of electronically recorded information on donor alcohol 
use prior to 2006, analysis of SPK transplants before this date was precluded 
and therefore the pancreas graft survival in this study reflects medium-term 
outcome only. Finally, the incidence of post-transplant pancreatitis, peri-
pancreatic collections, and donor duodenal segment leaks would also be of 
interest, but this data was not captured by the UK Transplant Registry. The 
causes of graft loss may also differ between the groups of patients, but 
immunological and non-immunological causes of pancreas graft loss can be 
difficult to distinguish, and are often not coded accurately in registry analyses 
 
Despite these limitations, we feel that this study provides some reassurance 
for surgeons considering pancreases from donors with an increased alcohol 
intake, though these organs require cautious back-table assessment. 
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